High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan ...

"Weight loss medications are not one size fits all and patients should always discuss options with a trusted medical professional," one expert told Newsweek.

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...

A European epilepsy drug could be an effective treatment for sleep apnea, a new study suggests. Patients who took sulthiame ...

An early-stage clinical trial found that sulthiame reduced sleep apnea 40 percent to 50 percent compared to placebo.

A common diabetes medication, metformin, slows the growth of precancerous cells in the esophagus while some metabolic ...